中心静脉导管与动静脉通路血液透析患者死亡率趋势比较
本研究利用美国肾脏数据系统,纳入2013-2022年起始血液透析的536,836例患者,采用克隆-删失-加权法比较持续使用中心静脉导管(CVC)与转为动静脉(AV)通路的死亡风险。结果显示两组18个月累积死亡风险均下降,CVC组从26.8%降至21.3%,AV组从20.9%降至17.1%,绝对风险差从5.9降至4.2例/100患者,相对风险从1.28降至1.25。
要点
- 过去十年CVC起始透析患者死亡率下降,CVC持续使用带来的绝对超额风险降低。
- CVC组18个月累积死亡风险从26.8%降至21.3%,AV通路组从20.9%降至17.1%。
- CVC与AV通路的绝对风险差从5.9降至4.2例/100患者,相对风险从1.28降至1.25。
核心结论
- 起始血液透析使用CVC的患者死亡率在过去十年下降,持续CVC使用的绝对超额风险相应减少。
研究设计与样本
- 观察性研究,纳入美国肾脏数据系统2013-2022年起始血液透析的社区居住、功能独立成人(18-85岁),共536,836例。
- 采用克隆-删失-加权因果推断方法比较持续CVC使用与转为AV通路,排除有成熟AV通路的患者以避免永恒时间偏倚。
- 使用逆删失概率加权离散时间池化逻辑回归模型评估18个月累积死亡风险,通路变化作为竞争事件。
主要发现
- CVC组和AV通路组分别发生71,443例和63,875例死亡。
- 2013至2022年,调整后18个月累积死亡风险在CVC组从26.8%降至21.3%,在AV通路组从20.9%降至17.1%。
- CVC与AV通路的绝对风险差从5.9(95%CI 5.4-6.3)降至4.2(95%CI 3.9-4.5)例/100患者,相对风险从1.28(95%CI 1.26-1.30)降至1.25(95%CI 1.23-1.27)。
- 血流感染相关死亡风险也呈类似下降趋势,绝对风险差和相对风险的降低幅度更大。
临床怎么用
- 临床应继续遵循指南优先使用AV通路,但需认识到CVC相关超额死亡风险已随时间降低。
- 对于起始透析使用CVC的患者,应积极评估并适时转换为AV通路以进一步降低死亡风险。
局限性
- 观察性研究设计,可能存在未测量混杂因素。
- 结果基于美国数据,外推至其他地区需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Guidelines favor arteriovenous (AV) access over central venous catheters (CVCs) for hemodialysis due in part to lower infection risk. Nevertheless, most patients initiate hemodialysis with a CVC. We used US Renal Data System data to evaluate whether the comparative mortality risk of these vascular access strategies has changed over time among patients with incident kidney failure. METHODS: In this observational study, we evaluated community-dwelling, functionally independent adults (aged 18-85 years) initiating hemodialysis with a CVC in 2013-2022, excluding those with a maturing AV access to prevent immortal time bias. We used the clone-censor-weighting approach, a causal inference method for evaluating dynamic treatment patterns, to compare continuous CVC use versus transition to an AV access. Inverse-probability-of-censoring weighted discrete-time pooled logistic regression modeled the 18-month cumulative risk of death by hemodialysis initiation year, with modality changes treated as competing events. RESULTS: Among 536,836 incident patients, 71,443 and 63,875 deaths occurred in the CVC and AV access groups, respectively. From 2013 to 2022, the adjusted 18-month cumulative risk of death declined from 26.8% to 21.3% in the CVC group, and from 20.9% to 17.1% in the AV access group. Correspondingly, the absolute risk difference comparing CVC versus AV access attenuated by nearly 30% (from 5.9 [95% CI 5.4, 6.3] to 4.2 [95% CI 3.9, 4.5] deaths per 100 patients), whereas the relative risk declined by 3% (from 1.28 [95% CI 1.26, 1.30] to 1.25 [95% CI 1.23, 1.27]). Bloodstream infection-related deaths showed similar declining risk patterns, with a proportionally larger attenuation in absolute risk difference and a greater decline in relative risk between groups. CONCLUSIONS: Mortality rates declined among patients initiating hemodialysis with a CVC over the past decade, which has led to a reduction in the absolute excess risk associated with continued CVC use.
引用
- Roetker NS, Wetmore JB, Liu J, et al. Trends in Mortality of Patients with Central Venous Catheters versus Arteriovenous Accesses for Hemodialysis. J Am Soc Nephrol. 2026. PMID: 42911666. doi:10.1681/ASN.0000001293
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。